BRUG: Buccal Cancer Resection Ultrasound Guided

Sponsor
UMC Utrecht (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05852665
Collaborator
Rijnstate Hospital (Other), University Medical Center Groningen (Other), Medisch Spectrum Twente (Other), Medical Center Haaglanden (Other), Antoni van Leeuwenhoek Ziekenhuis (Other)
50
1
30

Study Details

Study Description

Brief Summary

The aim of this research is to decrease the number of inadequate tumor-free margins, probably resulting in less adjuvant therapy, less local recurrences and better quality of life.

Condition or Disease Intervention/Treatment Phase
  • Device: Ultrasound-guided resection
N/A

Detailed Description

Buccal mucosa cancer is a rare disease. In the Netherlands, approximately 100 patients are treated for this disease each year. To obtain good local control, it is important that the histological distance from the tumor to the resection plane is 5 mm or more (tumor-free margin). If the tumor-free margin is smaller, such as close (1-5 mm) or involved (<1 mm) margins, there is usually an indication for adjuvant therapy. Now, the tumor-free margins in buccal mucosa cancer are often insufficient, so that a significant proportion of patients require adjuvant treatment (re-resection or radiotherapy). Postoperative radiotherapy can greatly reduce the quality of life due to the development of, for example, osteoradionecrosis, mucositis and fibrosis. During a re-resection it is often difficult to find the location of the insufficient margin. Ultrasound-guided resection can be used to visualize the tumor during surgery, in order to improve the tumor-free margins. Currently, the tumor-free margin is only estimated palpably and frozen sections are sometimes used in case of doubt.

The aim of this research is to decrease the number of involved margins, probably resulting in less adjuvant therapy, less local recurrences, and better quality of life.

In this trial, 50 patients with a squamous cell carcinoma of the buccal mucosa will be included for treatment with ultrasound-guided resection.

50 patients with a squamous cell carcinoma of the buccal mucosa, who will be treated with surgery under general anesthesia, will be included in this study. The tumor has to be visible as an hypo-echogenic region on the ultrasound.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Ultrasound-guided Resection of Buccal Mucosal Carcinomas - a Multicenter Study
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Mar 1, 2025
Anticipated Study Completion Date :
Mar 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Ultrasound-guided surgery

Device: Ultrasound-guided resection
Ultrasound-guided resection of buccal squamous cell carcinomas

Outcome Measures

Primary Outcome Measures

  1. Number of involved margins [within 2 weeks after surgery]

    Number of involved margins

Secondary Outcome Measures

  1. Sensitivity and specificity of ultrasound for identifying involved margins [within 2 weeks after surgery]

    accuracy of ultrasound

  2. Number of patients with an indication for local adjuvant therapy [within one month after surgery]

    need for local adjuvant treatment

  3. Quality of life assessed by questionnaires at 4 timepoints [before surgery, at 4, 8, and 12 months after surgery]

    Influence of treatment on quality of life

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • buccal mucosal squamous cell carcinoma

  • surgical removal under general anesthesia

Exclusion Criteria:
  • tumor is not visible on ultrasound as echolucent region

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • UMC Utrecht
  • Rijnstate Hospital
  • University Medical Center Groningen
  • Medisch Spectrum Twente
  • Medical Center Haaglanden
  • Antoni van Leeuwenhoek Ziekenhuis

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Rob Noorlag, Principal Investigator, UMC Utrecht
ClinicalTrials.gov Identifier:
NCT05852665
Other Study ID Numbers:
  • NL83714.041.23
First Posted:
May 10, 2023
Last Update Posted:
May 10, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Rob Noorlag, Principal Investigator, UMC Utrecht
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 10, 2023